Global Burkitt Lymphoma Therapeutics Market 2018-2022 - Key Vendors Are Biogen, F. Hoffmann-La Roche, Merck Sharp & Dohme, Novartis & Spectrum Pharmaceuticals - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 21, 2018--The “Global Burkitt Lymphoma Therapeutics Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
The Global Burkitt Lymphoma Market to grow at a CAGR of 3.07% during the period 2018-2022.
Burkitt lymphoma market 2018-2022 has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Increasing strategic alliances in the field of oncology will be one of the major trends in the market as vendors in the global oncology drugs market are regularly engaging in strategic alliances to strengthen their market position. Such alliances help these vendors consolidate their position and extend their geographical reach.
According to the report, one driver influencing this market is the rapid progression of Burkitt lymphoma requires immediate medical attention. Burkitt lymphoma is recognized as one of the fastest growing tumours in humans and is highly fatal if left untreated during the early stages.
Further, the report states that one challenge affecting this market is the high cost of the treatment. The chemotherapy drugs used in the treatment of Burkitt lymphoma are expensive. The high cost of chemotherapy drugs is one of the major challenges faced by the global Burkitt lymphoma therapeutics market.
Key vendorsBiogen F. Hoffmann-La Roche Merck Sharp & Dohme Novartis Spectrum Pharmaceuticals
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: DISEASE OVERVIEW
PART 05: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 06: MARKET SIZINGMarket definition Market sizing 2017 Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
PART 08: PIPELINE
PART 09: MARKET SEGMENTATION BY DRUG CLASSSegmentation by drug class Comparison by drug class Biological - Market size and forecast 2017-2022 Small molecule - Market size and forecast 2017-2022 Market opportunity by drug class
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPEGeographical segmentation Regional comparison Key leading countries Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
PART 16: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors
For more information about this report visit https://www.researchandmarkets.com/research/75nnhz/global_burkitt?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180921005401/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Lymphoma Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/21/2018 11:33 AM/DISC: 09/21/2018 11:33 AM